Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruisulin 30 vs NovoMix 30 in type 1 and 2 diabetes
CTR20130088Phase 3Active
- Start
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of myl-1601d in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change in glycated hemoglobin (HbA1c). Started May 2013; status: active.
02
Drugs
myl-1601d
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20130088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130088.